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Abstract 
 
Objective 
Precision medicine (PM) allows healthcare interventions to be tailored to groups of patients 
based on their disease susceptibility, diagnostic or prognostic information or treatment 
response. We analysed what developments are expected in PM over the next decade and 
considered the implications for health technology assessment (HTA) agencies.  
 
Methods 
We performed a pragmatic literature search to account for the large size and wide scope of 
the PM literature. We refine and enrich these results with a series of expert interviews up to 
one hour in length, including representatives from HTA agencies, research councils and 
researchers designed to cover a wide spectrum of precision medicine applications and 
research. 
 
Results 
We identified 31 relevant papers and interviewed 13 experts. We found that three types of PM 
are expected to emerge in clinical practice: complex algorithms, digital health applications and 
‘omics’-based tests. These are expected to impact upon each stage of the HTA process, from 
scoping and modelling through to decision-making and review. The complex and uncertain 
treatment pathways associated with patient stratification and fast-paced technological 
innovation are central to these effects.  
 
Discussion 
Innovation in PM promises substantial benefits but will change the way in which some health 
services are delivered and evaluated. The shelf-life of guidance may decrease, structural 
uncertainty may increase, and new equity considerations will emerge. As biomarker discovery 
accelerates and artificial intelligence-based technologies emerge, refinements to the methods 
and processes of evidence assessments will help to adapt and maintain the objective of 
investing in healthcare that is value for money. 
 
Key points 
¥ Three types of precision medicine technologies are likely to become more widespread 
in clinical practice over the next decade: ‘Omics’-based biomarkers; complex artificial 
intelligence-based algorithms; and digital health applications 
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¥ These innovations will require health technology assessment and guideline-producing 
agencies to adapt their methods and processes 
¥ The fast pace of discovery technological innovation, along with the potentially complex 
and uncertain treatment pathways patients will be presented with, are at the centre of 
the new challenges 
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1. Introduction 
 
Recent technological developments have allowed healthcare to be increasingly tailored 
toward specific patients and subgroups, a medical model referred to as precision medicine [1]. 
Broadly this process involves tailoring aspects of the patient pathway (i.e. advice, referral or 
treatment) based on their disease risk, prognosis or likely treatment response – a process that 
can yield additional benefits to patients and the wider healthcare system. The ‘precision’ is 
informed by tools that incorporate genetic, environmental and lifestyle information, and range 
from risk equations [2] to genetic testing [3]. 
 
Technological progress in precision medicine is expected to continue, spearheaded by 
programmes like the Precision Medicine Initiative [4] and the 100,000 Genomes Project [5]. 
This innovation will likely change the way that healthcare services are organised and 
delivered: the creation of new molecular testing infrastructure and the development of 
‘learning’ health information systems that analyse molecular and health record data to inform 
future prevention, detection or treatment strategies are two cited possibilities [6]. This will have 
consequences for the generation of clinical and economic evidence, meaning that healthcare 
decision makers, including health technology assessment (HTA) agencies and guideline 
producers, should consider how their methods and processes will accommodate these new 
technologies and services.  
 
HTA agencies’ experience of precision medicine has primarily been with diagnostic and 
companion diagnostic tests, the latter referring to those that identify biomarkers correlated 
with treatment response such as the HER2 receptor protein for breast cancer 
pharmacotherapies [3]. Several countries have accommodated the additional complexities of 
evaluating these tests through new procedures, such as the Diagnostic Assessment 
Programme at the National Institute for Health and Care Excellence (NICE) in England or the 
Health Technology Assessment Access Point in Australia [7, 8]. However, additional 
procedures may be required for other emerging precision medicine technologies.  
 
The objective of this study is to describe the possible landscape of precision medicine over 
the next decade, alongside the potential implications for HTA. Our analysis is the first to draw 
together the significant but disparate body of literature on the economics of precision 
medicine, present the potential issues arising at each stage of the decision-making process, 
and to anticipate future challenges by consulting with experts in a range of relevant fields. 
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2. Methods 
 
Our approach consisted of two components: a review of literature on the methodological and 
empirical challenges of precision medicine with respect to economic evaluation for HTA and 
a series of interviews with experts in fields related to precision medicine and/or healthcare 
decision-making. From these we determined the types of precision medicine technologies and 
services that are expected to emerge in the next decade and the challenges that these and 
existing technologies create for HTA.  
 
2.1. Literature Review 
 
We conducted searches to identify literature focusing on methodological considerations 
relating to guideline development, decision-making, and economic evaluation of precision 
medicine technologies, medicines, and healthcare.  
 
We searched MEDLINE and MEDLINE In-Process, prioritising retrieving relevant records at 
the expense of sensitivity. This pragmatic approach was taken because of the large size and 
wide scope of precision medicine literature. The search strategy was not intended to be 
exhaustive and instead aimed to retrieve those studies most likely to be relevant to the 
research question, while maintaining manageable numbers of records. A number of pragmatic 
decisions were made to limit record volume, including using only highly relevant search terms, 
restricting search terms to the title field, searching for English language publications only, and 
excluding publication types unlikely to yield study reports (e.g. news items). Rather than use 
pre-determined cut-off dates for inclusion, a flexible approach was adopted to provide an 
additional lever to limit record volume. This was anticipated to be from between 2007 and 
2012 up to the date the search was conducted (May 2017). We used supplementary search 
techniques to identify grey literature and unpublished research, with further articles identified 
through citation searches of included studies and author searches on a preliminary list of 11 
expert interviewees. The full search strategy is described in Appendix A. 
 
Articles were included if they (i) presented or assessed of methodological challenges relevant 
to economic evaluations of precision medicine, or (ii) discussed the implications of new or 
emerging precision medicine technologies. The number of topics considered relevant to 
economic evaluation was broad, and included guideline development, trial design, 
comparative effectiveness and health equity.  
 
Data were extracted from included papers by two reviewers (KE & AP). Consistency of 
approach was tested by comparing results from an initial single paper and discussing 
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discrepancies. Findings were tentatively organised into 11 pre-identified topic areas (provided 
in Appendix B), with new topics added where appropriate.  
 
2.2. Expert Interviews 
 
A list of experts was compiled based on prior familiarity to the authors and preliminary literature 
searches. Each met one of three criteria: (i) research outputs relating to precision medicine 
technologies and their evaluation; (ii) experience with decision making in HTA; and (iii) 
membership of institutes and organisations involving the use or evaluation of precision 
medicines. A total of 20 experts were contacted, all of whom were based in the UK. 
 
Semi-structured qualitative interviews [9] lasting between 30 to 60 minutes were conducted in 
person or via telephone by JLK and AP. A standardised document describing the key areas 
of inquiry was distributed to experts prior to interviews (see Appendix B). Interviewees were 
not required to contribute to every topic and were encouraged to raise additional relevant 
issues.  
 
A pattern coding approach was taken with the qualitative data, in which the contemporaneous 
notes taken during each interview were organised into the initial list of 11 topics, with new 
topics added where appropriate. Pattern coding was undertaken by one researcher (AP) and 
validated by a second (JLK), with disagreements resolved deliberatively. These data were 
then compiled across all interviews using Microsoft Excel. The combined findings from the 
review and interviews were independently assessed and discussed by three reviewers (JLK, 
KE & AP). 
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3. Findings 
 
3.1. Literature search & expert interview results 
 
A total of 549 records were identified from the searches, with an additional seven identified by 
the authors (Figure 1). In order to restrict the number of records to within our practical limit of 
300, articles published before 2011 were not considered for screening. It was assumed that 
any methodological issues identified in earlier literature would have either been resolved or 
reiterated in later articles. Screening on the basis of title, abstract and, where necessary, full 
texts left 31 included papers. 
 
Figure 1: Record flow diagram for pragmatic literature review 
 
 
Note: Of the 525 records excluded for eligibility reasons, 382 were based on abstract and full text 
review, with the remaining 143 removed due to being published prior to 2011. 
 
A total of 13 (65%) experts consented to be interviewed. Four represented the scientific affairs, 
technology appraisal, clinical guidelines and diagnostics assessment programmes at the 
NICE, and expressed their personal views, rather than Institute policy. Other interviewees 
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included four senior health economists, two researchers in digital health, a representative of 
the Medical Research Council (MRC), a specialist from the Precision Medicine Catapult 
institute and professors of health informatics and primary care sciences. The interviews had 
an average length of approximately 50 minutes.  
 
 
3.2. Defining precision medicine 
 
A preliminary consideration for this study was to define the types of technologies and services 
that precision medicine encompasses. Ten papers from the review provided a definition for 
precision medicine, as did each of the consulted experts, resulting in a wide range of 
interpretations [10-12]. Most agreed that precision medicine encompasses more than just 
pharmacogenetic and pharmacogenomic tests, and the term is now used interchangeably with 
stratified medicine. It is also replacing the term personalised medicine, as it also covers 
technologies that offer unique treatment pathways for individual patients [10, 11]. 
 
For the purposes of this study, we consider that a tool falls under the precision medicine 
‘umbrella’ if it can be used to stratify patients to a specific treatment pathway or therapy, based 
on specific characteristics of the individual. These characteristics vary by tool but go beyond 
demographic or socioeconomic factors, and include genomic (or other ‘omic’) information, 
behavioural traits (including preferences), and environmental and physiological 
characteristics. Furthermore, tools will usually provide information on disease risk, diagnosis, 
prognosis or treatment response. This definition is summarised in Figure 2. 
 
Figure 2: Defining precision medicine 
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Interviewees stressed an additional and important distinction between prognostic and 
predictive tests. Prognostic tests indicate the likelihood that an individual patient will have a 
particular disease course or natural history. For example, the Decipher prostate cancer test, 
which calculates the probability of metastasis [13].  Predictive tests provide an estimate of the 
expected disease response to specific treatments, such as tests identifying the human 
epidermal growth factor receptor (HER2) gene to determine treatment allocation for patients 
with breast cancer. This distinction has direct implications for HTA: a senior health economist 
highlighted a recent instance in NICE Diagnostics Guidance in which the committee’s 
discussions focused on whether the technology could be considered predictive as well as 
prognostic, since this had an impact on the cost-effectiveness of the test [14].   
 
3.3. Technological developments 
 
Three major types of precision medicine technology likely to emerge over the next decade 
were identified: complex algorithms, digital health applications (“health apps”), and ‘omics’-
based tests. These are summarised in the following sections and, alongside existing precision 
medicine tools, in Table 1. 
 
Complex algorithms 
Experts anticipated increased use of algorithms that use artificial intelligence (AI) to aid clinical 
decision-making over the next decade [15]. These algorithms require large data sets 
(“knowledge bases”) that include a large number of variables, such as genetic information, 
sociodemographic characteristics and electronic health records. Using this information, the 
algorithms provide clinicians and patients with predictions on expected prognosis and optimal 
treatment choices using patient-level characteristics. Algorithms update regularly as new 
information is added to the knowledge base, an approach termed “evolutionary testing”. The 
first approaches of this type for clinical use are already being established [16-20]. AI-based 
technologies will also be combined with advances in imaging to develop algorithms that 
incorporate scan results into knowledge bases to offer more accurate information [21].   
 
Health apps 
Health apps include a wide range of tools that provide disease management advice, receive 
and process patients-inputted data and record physical activity and physiological data such 
as heart rate. A subset of apps will likely fall under precision medicine, with the most advanced 
also utilising AI-based technology described above. Numbers of health apps are expected to 
increase significantly over the next decade. Digital health experts predicted that principal 
developments in this area would involve apps that analyse social or lifestyle determinants of 
health such as socioeconomic status or physical activity in order to stratify patients, including 
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apps linked to activity monitoring devices (or wearable technologies). In March 2017 NICE 
began to publish briefings on mobile technology health apps, known as “Health App Briefings”. 
One of the first to be published concerned Sleepio, an app shown in placebo-controlled clinical 
trials to improve sleep through a virtual course of cognitive behavioural therapy [22]. 
 
‘Omics’-based biomarkers 
Many current precision medicine tools use genetic and genomic information to estimate 
disease prognosis and predict treatment response [23]. A senior health economist predicted 
the use of other ‘omics’-based biomarkers, such as proteomics, metabolomics and lipidomics 
would become more common and partially replace genomics over the next decade.1  
 
‘Omics’-based testing is expected to increase in complexity and scope, with single tests 
informing treatment pathway, therapy choice or disease risk for multiple diseases 
simultaneously [24]. This was described by one expert as “multi-parametric testing”. Whole-
genome sequencing is at the broadest end of this scale and could feasibly provide information 
on risks and treatment decisions for hundreds of diseases [25].   
 
 
Table 1: Types of precision medicine technologies 
Type of technology or service 
Relevance to precision 
medicine 
Estimated timescales for 
use 
Tests for prognostic biomarkers 
Example: 
Decipher tests [13] - indicate risk of disease 
progression after prostate cancer diagnosis. 
Biomarkers indicate disease 
course and inform the patient 
treatment pathway. 
Genomic biomarkers are 
already in use. Rapid 
discovery of proteomic and 
metabolomic biomarkers is 
expected in the next five 
years. 
Tests for disease susceptibility biomarkers 
Example: 
Tests for BRCA1 gene - indicates risk of breast 
and ovarian cancer [26]. 
Biomarkers indicate risk of 
developing a particular 
condition and inform the patient 
treatment pathway. 
Tests for predictive biomarkers 
Example: 
HER2 protein tests – predicts response to 
breast cancer treatment [3].  
Biomarkers predict treatment 
response and inform therapy 
choice. 
An increasing number are 
being evaluated by HTA 
agencies – a review found 
NICE had evaluated seven 
by 2014 [8] 
 
                                               
1 These refer to fields of study that can identify biomarkers using proteins, metabolites and cellular 
lipids. These can be used instead of or in combination with genetic and genomic information. 
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Type of technology or service 
Relevance to precision 
medicine 
Estimated timescales for 
use 
 Expected to expand 
rapidly in next five years. 
Diagnostic services  
Including genetic, genomic and molecular 
testing services but also other types of 
diagnostic support for clinicians e.g. 
Computerised Decision Support [27].   
Services inform diagnoses and 
the patient treatment pathway. 
Some of these services are 
already in use. 
Complex algorithms 
Example: 
Sapientia [18] – combines genomic sequencing 
with clinical phenotyping to inform treatment 
decisions. 
Clinical, genomic, behavioural 
(and more) data are utilised by 
these algorithms to inform 
diagnosis, recommendations 
for patient treatment pathways 
and therapy choices. 
Several are being 
developed and trialled – 
expected to be in clinical 
practice within the next 
decade. 
Expected to be artificial 
intelligence-based as the 
field progresses (e.g. AI 
Biocomputing [28]). 
Digital health applications 
Example: 
MyHeart Counts [29] – records and analyses 
data on activity, risk factors and haematology, 
providing suggestions on improving heart 
health. 
Apps draw on clinical and 
behavioural data and aim to 
influence patient behaviour, 
healthcare use and/or choice of 
treatment. 
Apps are already available 
but numbers are expected 
to increase dramatically in 
next decade. 
Risk prediction tools 
Example: 
QRISK [30] – static algorithm that determines 
risk for cardiovascular disease and informs 
statin prescribing. 
Patient histories and 
characteristics (e.g. BMI, co-
morbidities) are used to 
calculate disease risk, 
informing the patient treatment 
pathway. 
Currently available for a 
wide range of clinical 
areas. 
Patient decision aids 
Example: 
MAGIC [31] – produces dynamic decision aids 
that update based on published guidelines   
Instruments support patients in 
making decisions tailored to 
their preferences. 
Currently available for a 
wide range of clinical 
areas. 
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Figure 3: Challenges for health technology assessment agencies raised by precision medicine 
 
Note: The first-tier categories (scoping to review) relate to the four principal stages of a typical health 
technology assessment appraisal, such as that used by National Institute for Health and Care 
Excellence in England for traditional pharmaceutical technologies [32]. 
 
 
3.4. Issues for HTA 
 
Precision medicine interventions will pose challenges at each stage of the HTA process, from 
scoping through to review (Figure 3).  
 
3.4.1. Scoping 
The nature of the decision problem presented to HTA agencies and guideline developers will 
become more difficult to define when dealing with some precision medicine technologies and 
services. The emergence of multi-parametric tests, for instance, is expected to increase the 
number of relevant interventions, comparators and populations encompassed by a single 
assessment by providing information on multiple diseases simultaneously. The number of care 
pathways under consideration will also increase because tests (i) may not have a defined 
place in the care pathway and could potentially be used at a range of time points and (ii) may 
be used in combination with other tests [33-37]. Evaluating all of the relevant pathways, 
populations, and comparators could be practically and computationally infeasible, and will 
likely necessitate increased use of expert opinion [11, 33, 38, 39, 34, 35]. One expert noted 
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that these issues are particularly relevant for whole-genome sequencing, which can be 
performed at any point during an individual’s lifetime, inform care pathways for a wide range 
of diseases, and be analysed using many different methods [37]. 
 
The fast pace of innovation in precision medicine may also mean that assessment bodies face 
higher volumes of evaluations. Mixed views on how to address this emerged from expert 
interviews. A NICE analyst stated that scoping workshops, in which clinicians and other 
consultees determine which technologies should be evaluated, may be sufficient for 
technology appraisal. With respect to health apps, researchers agreed that new systems 
would need to be put in place to manage the burden of assessment. This could involve (i) a 
preliminary self-assessment phase, (ii) appraising classes of (rather than individual) apps, or 
(iii) setting priority areas using clinician input. Each present their own difficulties: classes would 
need to contain apps that are relatively homogenous, whilst any priority setting process would 
require a clear and transparent decision-making framework. 
 
Experts highlighted that adaptive AI-based algorithms would present a unique challenge in 
terms of regulation and evaluation. As more data are processed and the algorithm becomes 
more effective over time, evaluators would need to decide how frequently and exactly when 
to assess safety and clinical and cost-effectiveness [40]. Interviewees also highlighted that 
technical validation of complex algorithms could be a challenge [41]. 
 
3.4.2. Modelling 
 
Measuring value 
A number of studies stated that the value placed on knowing diagnostic test results may need 
to be included in economic evaluations of precision medicine [42, 43, 39, 44-47, 35, 48-50]. 
This could be positive if such knowledge benefits patients and their families: directly in the 
case of hereditary conditions [12], or indirectly through enhanced autonomy or changes in 
lifestyle and screening behaviours [50]. Conversely, unintentional harms may also occur, for 
example due to psychological stress for patients and families.   
 
Experts highlighted that the health-related quality of life instruments typically used in economic 
evaluations are unlikely to capture this value of knowing and that decision-makers may instead 
consider these factors through deliberation, taking into account the patient perspective, when 
making recommendations. Three studies [12, 44, 35] suggested that discrete choice 
experiments could be used to value patient preferences for increased knowledge, over and 
above any specific QALY gains deriving from subsequent treatment decisions. Quantifying 
these benefits separately (or in monetary terms) would be consistent with a welfarist 
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framework but not the extra-welfarist one adopted by some agencies such as NICE [51]. 
Furthermore, incorporating these additional aspects of value on the benefits side of the cost-
effectiveness equation also requires that they be incorporated when accounting for opportunity 
costs [52]. Incorporating non-health benefits into the evaluative framework of HTA would 
therefore require knowledge of (i) the extent to which society is willing to trade-off health and 
non-health benefits and (ii) what type of services might be displaced in order to fund a new 
intervention, and their associated non-health benefits. 
 
Evidence evaluation and synthesis 
Precision medicine presents numerous challenges for evidence evaluation. The stratification 
of patients to increasingly small subgroups will reduce sample sizes [10, 44, 53] and result in 
only certain subgroups (i.e. ones with specific biomarkers) being included in individual trials. 
Obtaining head-to-head estimates of comparative effectiveness for treatments and subgroups 
will become more difficult and will result in evidence networks being incomplete in cases where 
no common comparator links together the available trials. One study and several of the 
interviewees concluded that expert opinion will be needed more regularly to fill gaps in the 
evidence [12], along with suitably robust methods for eliciting these judgements [46].  
Interviewees also noted that new trial designs are being developed that may be more 
compatible with precision medicine, including basket, umbrella and adaptive trials [54-56]. 
These designs, which are yet to contribute to any value dossiers submitted to HTA agencies, 
allow for trials to be adapted in terms of inclusion criteria and treatment response.  
 
Nevertheless, the need to analyse multiple subgroups and more complex treatment pathways 
in decision models for precision medicine interventions is likely to necessitate additional 
sources of evidence [12], in terms of both cost and clinical data [39, 34, 38, 33, 53, 36, 35]. 
An absence of relevant data recently resulted in the discontinuation of a diagnostic service 
delivery guideline being developed by NICE [57]. Regulatory efforts are being made to 
encourage the generation of clinical evidence, including the introduction of the In Vitro 
Diagnostic Device Regulations (IDVR) in 2017 by the European Commission [58]. However, 
as the new clinical evidence requirements for approval of the IDVR will not apply until 2022, 
evidence paucity is likely to an issue in Europe in the medium term.  
 
There was consensus that use of observational data for assessing precision medicine 
interventions will increase over the next decade [11, 36, 39, 44, 33], including registry data, 
cohort studies and electronic health records [59, 16, 60]. Experts noted that advanced 
statistical methods (and accompanying technical guidance) would be required to identify 
causality while controlling for the risks of selection bias and confounding in observational data.  
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Decision analytic modelling 
Multiple studies predicted that the complexity of clinical pathways in precision medicine could 
render traditional Markov-type model structures insufficient for capturing long-term costs and 
benefits [42, 61, 43, 12, 10, 35]. For example, multi-parametric testing may lead to secondary 
findings unrelated to the original test, as well as spill-over effects on family members and 
future generations [48]. A number of studies concluded that more research is needed to 
establish best practice guidelines for modelling precision medicines [43, 60, 33, 12], while 
others suggested approaches that could handle complex structures more adequately, such as 
microsimulation and discrete event simulations [35, 12, 62]. 
 
3.4.3. Decision-making 
 
Uncertainty 
The stratification of a patient population may result in smaller sample sizes recruited to trials 
for precision medicine interventions. Combined with more complex and variable treatment 
pathways, this could increase levels of uncertainty associated with cost-effectiveness 
estimates presented to decision makers. 
 
Higher standard errors for estimates of treatment effect were raised as a concern [42, 61, 36, 
11, 43, 60, 35, 46]. Several experts believed, however, that this concern is overstated. First, 
treatment effect variation between patients should be lower when therapies are targeted 
towards responders, thereby reducing standard errors. Second, any reduction in sample sizes 
could be compensated for in time through the use of large, linked observational datasets [16]. 
Value of information analysis, a technique for quantifying the value of reducing decision 
uncertainty, was also identified as key technique that could be beneficial to decision making 
[12, 33, 44, 60, 63, 64]. Along with more typical factors such as patient population size, the 
key determinants of value of information in precision medicine will include the sensitivity and 
specificity of tests and predictions, and the intervention context (i.e. if it is used in combination 
with other tests).  
 
Another source of uncertainty will be the unit costs, for example of ‘omics’-based tests, which 
vary by laboratory [36]. Such tests may also yield continuous results, meaning that thresholds 
must be set to determine the outcome of testing [11]. Thresholds will impact on the cost-
effectiveness of tests and, therefore, it was argued that determination of thresholds should go 
beyond analysis of receiver operating characteristic curves [12]. 
 
Complex clinical pathways will generate substantial uncertainties over model structure in 
economic evaluations of precision medicine interventions. Many experts and studies 
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highlighted this as a critical aspect of decision modelling that would need to be addressed [35, 
39, 33, 43, 11, 36]. Whilst it was agreed that the current approach of extensive sensitivity and 
scenario analyses should continue, interviewees expressed a desire for coherent frameworks 
for analysing and quantifying structural uncertainties. Approaches highlighted in the literature 
included multi-parameter evidence synthesis, although this approach may also be impeded 
by sparse data [65]. Value of information-type approaches can help to quantify the extent of 
this uncertainty and the value of reducing it, through techniques such as expert elicitation [66]. 
 
An additional consideration is uncertainty around the behaviour of clinicians and patients. 
Decisions made by these individuals, for example whether to follow the treatment pathway 
indicated by the result of a diagnostic test, could influence how clinically effective the 
intervention is and, thus, impact cost-effectiveness [12, 43, 33, 38, 44, 34, 39]. In terms of 
clinician behaviour, low compliance to genotype-specific dosing recommendations has been 
observed [33]. Steep learning curves for some stratification tools have also been suggested 
as a cause of variability [67]. On the patient side, adherence remains an important yet under-
researched determinant of effectiveness [36]. The development and application of evidence-
based computerised decision support and patient decision aids could be a way to tackle these 
challenges. 
 
Equity and equality 
When generating guidance that recommends different courses of treatment for different 
groups of patients, HTA agencies and other public bodies should aim to ensure that principles 
of non-discrimination and equality of opportunity are advanced [68, 69]. The main challenge 
lies in the specific instances where there are small numbers of patients in rare biomarker-
stratified groups, for whom there is greater uncertainty around treatment effects [70]. An 
equality issue arises when the biomarkers used for stratification are correlated with factors 
such as ethnicity [53, 36]. In the NICE appraisal of sofosbuvir for treating chronic hepatitis C 
[71], low levels of evidence were available for some genotypes that were more common in 
minority ethnic patients. In this instance, a “pragmatic” approach was explicitly taken on the 
grounds of equity, high unmet need and the lack of treatment options; evidence was 
extrapolated from genotypes where the treatment’s effectiveness was well-supported and the 
therapy was recommended for the rarer genotypes.  
 
Stratifying patients to different treatment pathways based on measures of physiological 
dysregulation (such as blood pressure or cortisol level) may also introduce equity concerns. 
A significant, negative association between these measures and socioeconomic status has 
been established in the literature [72]; differential treatment recommendations may therefore 
result in individuals from low socioeconomic groups having a lower probability of receiving the 
The Future of Precision Medicine: Potential Impacts for Health Technology Assessment 
18 
 
most effective treatments. Concerns were also raised with respect to the differential uptake of 
some precision medicine interventions that require patient engagement. This is particularly 
true in digital health, where experts reported that use of health apps was much more common 
in younger age groups and those with higher social and educational status. If traditional (i.e. 
GP-delivered) services were to be withdrawn in favour of digital-only access, the benefits of 
precision medicine may be unevenly distributed.  
 
3.4.4. Review / update 
 
Experts working for HTA agencies noted that the rate of discovery of biomarkers means that 
the specificity and sensitivity of companion diagnostic tests is expected to steadily improve. 
Similarly, health apps and AI-based algorithms are regularly updated and upgraded, meaning 
that certain treatment pathways might become more cost-effective over time. Although 
beneficial, this could reduce the ‘shelf-life’ of guidance issued by HTA agencies and 
necessitate more frequent reviews and updates [35]. NICE have already begun addressing 
this issue with  innovations to fast-track some evaluations [73] and increase the capacity of 
the technology appraisals programme [74].  Similar combined approaches to streamlining 
processes and increasing capacity will help the HTA community keep guidance up-to-date 
and useful while keeping the overall cost of HTA manageable.  
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4. Discussion 
 
This study aimed to take a forward-looking view of precision medicine, considering what 
challenges are likely to be faced by HTA and guideline producing agencies as precision 
medicine technologies and services become more prevalent (see Appendix C for a brief 
demonstrative case study).  
 
We identified three key areas of precision medicine that are expected to expand in the next 
decade: complex algorithms, health apps and ‘omics’-based tests. The potential benefits to 
patients from these technologies are substantial, particularly as the costs of ‘omics’ testing are 
likely to decrease and manufacturers will be able to develop targeted therapies with greater 
efficiency. Complex algorithms and health apps will utilise AI and large, linked datasets to 
adapt all aspects of healthcare to patient sub-groups and individuals in order to improve health 
outcomes. Additional technologies that were not discussed by experts or in the literature, such 
as the genome editing technique CRISPR [75], are also likely to fall under the umbrella of 
precision medicine as their application in healthcare is developed.  
 
These new technologies will inevitably present challenges to decision makers. Researchers 
and clinicians should remain aware that it will not always be beneficial or ethical to use 
biomarker information to inform treatment decisions. Examples are already emerging of 
instances where a seemingly informative biomarker has not added predictive power to risk 
equations [76].  
 
Early consideration of the evidence required by decision-makers can improve evidence 
collection and analysis for precision medicine technologies and services in very early stages 
of development [77]. Innovative approaches for evidence generation to facilitate this are 
currently being developed: new trial designs [55] and robust statistical methods for analysing 
observational data [78] will help fill evidence gaps and improve trial recruitment numbers. 
Additionally, increasing use of health apps can improve the quality, frequency and accuracy 
of data collection.  
 
Clear and transparent processes and principles will also be necessary to ensure equitable 
decision making, particularly in cases where biomarkers are correlated with factors such as 
ethnicity and sociodemographic status. As with interventions such as vaccination and cancer 
screening [79, 80], unequal uptake of some precision medicines is also an area of concern 
that policy makers may want to consider and design strategies to counteract, such as targeting 
programmes. 
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Furthermore, it is not yet clear if any European agencies will be responsible for evaluating the 
safety, clinical- and cost-effectiveness of health apps and AI-based technologies. Addressing 
this regulatory and assessment vacuum is necessary to promote the uptake of safe and 
effective products. Evaluating these types of tools not only requires a new technical expertise 
within HTA agencies, but perhaps even a different system altogether given (i) the pace of 
innovation and (ii) the regularity with which apps and algorithms are updated, which can alter 
their effectiveness and cost-effectiveness. Historical examples of assessments of these 
technologies by HTA agencies are sparse; developing a better understanding of the most 
appropriate approach for robustly evaluating AI-based technology should therefore be a 
valuable area of further research.  
 
Resolving some of the issues presented in this paper, such as scoping increasingly complex 
treatment pathways, may require a thorough and balanced evaluation of the strengths and 
potential shortcomings of normative choices within an HTA framework,. Any departure from 
current established frameworks will require considerable deliberation and co-operation 
between a wide range of stakeholders from across the health system. An appropriate solution 
will be dependent upon on (i) the decision-making context within which the HTA agency exists, 
(ii) the stated objectives of the health system as a whole and (iii) the practicality of the 
assessment and (iv) the relevance of the framework to the technology type [81].  
 
A number of European organisations, such as ICPerMed, EUnetHTA and Horizon 2020, have 
identified the health economic evaluation of precision medicines as an important area of 
research [82-84]. The conclusions of these initiatives, which are at this point undetermined, 
can help to seeking to address some of the other methodological issues we have highlighted, 
such as evidence generation and synthesis. 
 
Strengths and limitations 
Whilst other studies have analysed the potential consequences of precision medicine on HTA 
processes [60, 38], the focus has been restricted to diagnostic and companion diagnostic 
tests. The more expansive definition of precision medicine adopted in this review, which 
includes technologies substantively different to diagnostics, therefore highlights a number of 
novel issues on the horizon for HTA agencies that will be realized in an evolving regulatory 
landscape.  
 
However, our findings are limited by several factors. First, our qualitative interviews were 
conducted with UK-based experts only. Although the wider scope of the literature review also 
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helps to relax the UK-centricity of the findings, future research should look implications in other 
settings. This need aligns with the research objectives of the cross-country initiatives noted 
above. 
 
Second, for practical reasons we made several pragmatic decisions when conducting the 
literature review. This may have resulted in relevant articles that being excluded from our 
analysis, resulting in overlooked insights and issues.   
 
Our review also primarily focused on the implications of precision medicine technologies on 
HTA rather than identifying those expected to come into practice in the decade. We were 
therefore more reliant on expert opinion for this aspect of the results. 
 
5. Conclusion 
 
Precision medicine interventions are likely to proliferate over the next decade and will change 
the way services are delivered and evaluated. It is possible to speculate that such changes 
will be driven firstly by the complexity and uncertainty around delivering therapies that use 
biomarker data and, secondly, by the innovative, evolutionary nature of AI-based 
technologies. Healthcare systems around the world will need to consider adjusting their 
evaluative methods and processes to accommodate these changes in such a way that they 
can continue to robustly assess the value-for-money of new treatments and services.  
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